Table 2 Demographic data and laboratory investigations of the studied patients according to PCR for HBV DNA after end of HCV treatment

Patients without HBV reactivation after HCV treatment (N = 184)

Patients with HBV reactivation after HCV treatment (N = 16)

P value

Age (years)

 Mean ± SD

44.86 ± 7.45

48.25 ± 4.64

0.076

 Min–Max

24–63

41–58

N = 184

%

N = 16

%

Sex

 Male

102

55.4%

13

81.3%

0.045

 Female

82

44.6%

3

18.7%

Laboratory investigations

Mean ± SD

Min–Max

FBS (mg/dL)

95.74 ± 26

90.81 ± 20.12

0.46

Hb (g/dL)

13.01 ± 1.1

13.29 ± 1.1

0.33

WBC (× 10³)

6.47 ± 1.04

6.98 ± 0.82

0.06

Platelets (× 10³)

179.7 ± 59.3

170.25 ± 50.19

0.53

ALT (U/L)

35.53 ± 10.81

41.56 ± 19.27

0.049

AST (U/L)

39.66 ± 18.18

41.56 ± 14.14

0.73

Albumin (g/dL)

3.89 ± 0.22

3.8 ± 0.3

0.16

Creatinine (mg/dL)

0.74 ± 0.09

0.79 ± 0.1

0.042

INR

1.11 ± 0.1

1.08 ± 0.12

0.21

PC (%)

92.09 ± 7.62

93.74 ± 8.25

0.41

Total bilirubin (mg/dL)

0.55 ± 0.25

0.54 ± 0.29

0.98

Direct bilirubin (mg/dL)

0.18 ± 0.03

0.17 ± 0.04

0.43

AFP (ng/mL)

4.64 ± 1.63

4.92 ± 2.53

0.86

Liver stiffness (kPa)

8.87 ± 3.46

6.44 ± 1.66

0.07

HCV RNA Level (Iu/ml)

1.15 × 10⁵ ± 2.34 × 10⁵

2.92 × 10⁵ ± 1.87 × 10⁵

0.047